-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Penile Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Penile Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Penile Cancer Drug Details: Atezolizumab (Tecentriq) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in T-Cell Acute Lymphocytic Leukemia...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: WU-CART-007 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Posoleucel in Epstein–Barr Virus (HHV-4) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Posoleucel in Epstein–Barr Virus (HHV-4) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Posoleucel in Epstein–Barr Virus (HHV-4) Infections Drug Details: Posoleucel (ALVR-105)...
-
Product Insights
NewLymphoblastic Lymphoma – Drugs In Development, 2024
Empower your strategies with our Lymphoblastic Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Lymphoblastic lymphoma (LL) is a rare and aggressive type of non-Hodgkin lymphoma (NHL) that affects immature lymphocytes called lymphoblasts. It can originate from either B-cell or T-cell lymphoblasts, but it is more common in T cells. LL usually involves the lymph nodes in the chest, but it can also affect the bone marrow, the brain and spinal cord, and other organs. LL...
-
Product Insights
NewT-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024
Empower your strategies with our T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024 report and make more profitable business decisions. T-cell acute lymphoblastic leukemia (T-ALL) is a type of blood cancer that affects T-cell lymphocytes, a type of white blood cell involved in the immune system's function. T-ALL originates from immature T-cells in the bone marrow that fail to mature into normal functioning T-cells. These abnormal cells grow rapidly, crowding out normal blood cells (red blood...
-
Product Insights
NewCutaneous T-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Cutaneous T-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). These cells normally help body's germ-fighting immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin. Originating in T lymphocytes, it causes skin alterations like red, scaly patches or itchy plaques, progressing slowly...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Acute Myeloid Leukemia in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy For Acute Myeloid Leukemia in Myelodysplastic Syndrome Drug Details: The drug candidate is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Acute Myeloid Leukemia in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy For Acute Myeloid Leukemia in Refractory Acute Myeloid Leukemia Drug Details: The drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Acute Myeloid Leukemia in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy For Acute Myeloid Leukemia in Relapsed Acute Myeloid Leukemia Drug Details: The drug...